Mga Batayang Estadistika
| CIK | 1733294 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Generation Bio Co.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 12, 2025 |
Exhibit 99.1 CONFIDENTIAL Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results ● New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates ● Lead siRNA candidates show potent knockdown of LAT1 and VAV1, targets poten |
|
| August 12, 2025 |
Form of Nonstatutory Stock Option Agreement under 2025 Inducement Stock Incentive Plan Exhibit 10.2 Generation Bio Co. NONSTATUTORY STOCK OPTION AGREEMENT Granted under 2025 Inducement Stock Incentive Plan Generation Bio Co. (the “Company”) hereby grants the following stock option to the recipient named below pursuant to its 2025 Inducement Stock Incentive Plan (as amended through the date hereof, the “Plan”). The terms and conditions attached hereto are also a part hereof and are i |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 12, 2025 |
2025 Inducement Stock Incentive Plan Exhibit 10.1 2025 INDUCEMENT STOCK INCENTIVE PLAN OF GENERATION BIO CO. 1. Purpose The purpose of this 2025 Inducement Stock Incentive Plan (the “Plan”) of Generation Bio Co., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GEN |
|
| July 18, 2025 |
Generation Bio Announces 1-for-10 Reverse Stock Split Exhibit 99.1 Generation Bio Announces 1-for-10 Reverse Stock Split CAMBRIDGE, Mass. – July 18, 2025 – Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 reverse stock split of the issued shares of the Company’s common stock (“Reverse Stock Split”), e |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 18, 2025 |
Certificate of Amendment of Amended and Restated Certificate of Incorporation of Generation Bio Co. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENERATION BIO CO. Generation Bio Co., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Generation Bio Co. The date of filing of the Corporation’s original Certificate of I |
|
| June 5, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 7, 2025 |
Exhibit 99.1 Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results - Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and portfolio strategy to be announced MY 2025 - Cash balance of $157.6 million exp |
|
| May 7, 2025 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Generation Bio Co. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GE |
|
| May 7, 2025 |
Form of Nonstatutory Stock Option Agreement Granted under 2025 Inducement Stock Incentive Plan. Exhibit 99.2 Generation Bio Co. NONSTATUTORY STOCK OPTION AGREEMENT Granted under 2025 Inducement Stock Incentive Plan Generation Bio Co. (the “Company”) hereby grants the following stock option to the recipient named below pursuant to its 2025 Inducement Stock Incentive Plan (as amended through the date hereof, the “Plan”). The terms and conditions attached hereto are also a part hereof and are i |
|
| May 7, 2025 |
As filed with the Securities and Exchange Commission on May 7, 2025 As filed with the Securities and Exchange Commission on May 7, 2025 Registration No. |
|
| May 7, 2025 |
2025 Inducement Stock Incentive Plan of Registrant. Exhibit 99.1 2025 INDUCEMENT STOCK INCENTIVE PLAN OF GENERATION BIO CO. 1. Purpose The purpose of this 2025 Inducement Stock Incentive Plan (the “Plan”) of Generation Bio Co., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to |
|
| April 23, 2025 |
Table of Contents will UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Filed by a Party other than the Registrant ☒ Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 11, 2025 |
Table of Contents will UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 13, 2025 |
Offer letter, dated December 8, 2017, by and between the registrant and Phillip Samayoa, as amended. Exhibit 10.20 Generation Bio Co. December 8, 2017 Phillip Samayoa Dear Phillip: On behalf of Generation Bio. Co. (the "Company"), I am pleased to offer you employment with the Company on the following terms and conditions. 1. Position. You will be employed by the Company as a Senior Director of Corporate Development and Portfolio Strategy. It is contemplated that you will commence employment on a |
|
| March 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 13, 2025 |
Subsidiaries of the registrant. Exhibit 21.1 Subsidiaries of the Registrant Entity Jurisdiction of Incorporation Generation Bio Securities Corporation Massachusetts |
|
| March 13, 2025 |
Non-Employee Director Compensation Program. Exhibit 10.18 GENERATION BIO CO. Non-Employee Director Compensation Program Under Generation Bio Co.’s (the “Company”) non-employee director compensation program, the Company pays its non-employee directors an annual fee. Each non-employee director receives an annual fee for service on the Company’s board of directors (the “Board”) and for service on each committee on which the director is a membe |
|
| March 13, 2025 |
Offer letter, dated December 8, 2017, by and between the registrant and Kevin Conway, as amended. Exhibit 10.28 By Electronic Mail June 25th, 2019 Kevin Conway RE: Offer of Employment Dear Kevin: We are very excited to offer you the position of Assistant Corporate Controller where you will play an essential role in building Generation Bio's foundation and long -term business and scientific success. Below are the terms of employment for your review and execution. If these terms are acceptable, |
|
| March 13, 2025 |
Separation Agreement, by and between the registrant and Matt Norkunas, dated January 13, 2025. Cambridge, MA 02142 generationbio.com Exhibit 10.29 January 4, 2025 BY E-MAIL *** Dear Matt: This letter agreement (the “Agreement”) confirms the terms of your separation from employment at Generation Bio Co. (the “Company”)1. This Agreement will become effective and enforceable on the eighth day after you sign it without revocation (the “Effective Date”), provided you sign and return the Agreemen |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 13, 2025 |
Exhibit 99.1 Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025 - Cash balance of $185.2 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., Mar. 13, 202 |
|
| March 13, 2025 |
Cambridge, MA 02142 generationbio.com Exhibit 10.30 January 3, 2025 BY E-MAIL Matthew Stanton *** *** Dear Matt: This letter agreement (the “Agreement”) confirms the terms of your separation from employment at Generation Bio Co. (the “Company”)1 and the Company’s interest in securing your agreement to provide transition services on an as-needed basis and sets forth the terms and conditions to whic |
|
| February 28, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 6, 2025 |
Exhibit 99.1 Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo - Programs to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseases - Company reorganization |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 3, 2025 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Generation Bio Co. |
|
| January 3, 2025 |
As filed with the Securities and Exchange Commission on January 3, 2025 As filed with the Securities and Exchange Commission on January 3, 2025 Registration No. |
|
| December 9, 2024 |
GBIO / Generation Bio Co. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d891686dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 5, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate t |
|
| November 6, 2024 |
Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results ● Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) ● Cash balance of $199. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3931 |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 13, 2024 |
August 13, 2024 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Generation Bio Co. |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 7, 2024 |
Exhibit 99.1 Generation Bio Reports Second Quarter 2024 Financial Results ● Cash balance of $217 million still expected to fund operations into 2H 2027 CAMBRIDGE, MASS., Aug. 7, 2024 - Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2024 financial results. “We |
|
| August 7, 2024 |
Exhibit 1.2 GENERATION BIO CO. $237,000,000 SALES AGREEMENT August 7, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue, 11th Floor New York, New York 10017 Ladies and Gentlemen: Generation Bio Co., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from tim |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GEN |
|
| August 7, 2024 |
Form of Subordinated Indenture Exhibit 4.4 GENERATION BIO CO. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Ina |
|
| August 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Generation Bio Co. |
|
| August 7, 2024 |
Exhibit 4.3 GENERATION BIO CO. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplicab |
|
| August 7, 2024 |
Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| August 7, 2024 |
As filed with the Securities and Exchange Commission on August 7, 2024 Table of Contents As filed with the Securities and Exchange Commission on August 7, 2024 Registration No. |
|
| August 7, 2024 |
Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| June 7, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GE |
|
| May 13, 2024 |
Separation Agreement, by and between the registrant and Doug Kerr, dated January 28, 2024. Exhibit 10.1 Cambridge, MA 02142 generationbio.com November 29, 2023 Doug Kerr *** *** Re:Separation Agreement Dear Doug: This letter confirms the terms of your transition and separation from employment at Generation Bio Co. (the “Company”).1 As we discussed, the Company is reorganizing and, as a result, your position is being eliminated. You will continue to work and effect a transition of your d |
|
| May 13, 2024 |
Consulting Agreement, by and between the registrant and Doug Kerr, dated February 1, 2024. Exhibit 10.3 CONSULTING AGREEMENT GENERATION BIO CONTRACT NO. 21520 This Consulting Agreement (the “Agreement”) dated February 1, 2024 (the “Effective Date”), is made by and between Generation Bio Co., a Delaware corporation having a place of business at 301 Binney St., Suite 401, Cambridge, MA 02421 (the “Company”), and Douglas Kerr, an individual with an address at *** (the “Consultant”). WHEREA |
|
| May 13, 2024 |
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results - Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP) - ASGCT poster presentations described immune-quiet DNA (iqDNA) as partially single-stranded, produced by flexible, scalable, proprietary rapid enzymatic synthesis - Cash balance of $233. |
|
| May 13, 2024 |
Separation Agreement, by and between the registrant and Tracy Zimmermann, dated January 28, 2024. Exhibit 10.2 Cambridge, MA 02142 generationbio.com November 29, 2023 Tracy Zimmermann *** *** Re:Separation Agreement Dear Tracy: This letter confirms the terms of your transition and separation from employment at Generation Bio Co. (the “Company”).1 As we discussed, the Company is reorganizing and, as a result, your position is being eliminated. You will continue to work and effect a transition o |
|
| May 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 24, 2024 |
Table of Contents will UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Filed by a Party other than the Registrant ☒ Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 6, 2024 |
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia - Development of breakthrough immune-quiet DNA for hemophilia A program continues - Cash balance of $264. |
|
| March 6, 2024 |
Subsidiaries of the registrant. Exhibit 21.1 Subsidiaries of the Registrant Entity Jurisdiction of Incorporation Generation Bio Securities Corporation Massachusetts |
|
| March 6, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Generation Bio Co. |
|
| March 6, 2024 |
As filed with the Securities and Exchange Commission on March 6, 2024 As filed with the Securities and Exchange Commission on March 6, 2024 Registration No. |
|
| March 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 6, 2024 |
Insider Trading Policy of the registrant. Exhibit 19.1 GENERATION BIO CO. Insider Trading Policy 1. BACKGROUND AND PURPOSE The federal securities laws prohibit any member of the Board of Directors (a “Director”), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), an “executive officer”) or employee of Generation Bio Co. (together with its subsidiaries, the “Company”) from purchasing or sel |
|
| March 6, 2024 |
Compensation Recovery Policy of the registrant. Exhibit 97.1 Generation Bio Co. Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Generation Bio Co. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Dodd-Frank Wall Street Reform a |
|
| February 13, 2024 |
GBIO / Generation Bio Co. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 9, 2024 |
GBIO / Generation Bio Co. / Atlas Venture Fund X, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm245794d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Generation Bio Co. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the app |
|
| February 2, 2024 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 31, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 29, 2023 |
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms - Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell types - Development of immune-quiet DNA (iqDNA) platform for lead hemophilia A program to continue - Strategic reorganization will result in a 40% reduction of workforce - Anticipated cost savings to extend cash runway into 2H 2027 CAMBRIDGE, MASS. |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 27, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3931 |
|
| November 9, 2023 |
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results - Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics - Proprietary cell-targeted LNP delivery system showed highly selective T cell transduction in humanized mouse model, demonstrating in vivo targeting for T cells and potentially for other extrahepatic tissues and cell types - Third quarter 2023 cash balance of $291. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 26, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 26, 2023 |
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform - 70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells - Stealth properties of cell-targeted lipid nanoparticle (ctLNP) platform confirmed in non-human primates, demonstrating prolonged circulation and less than 0. |
|
| October 18, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 18, 2023 |
Medicine Platform with Novel “Immune-Quiet” DNA Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA -Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and tolerability comparable to mRNA -Company is advancing iqDNA in lieu of prior ceDNA constructs a |
|
| August 2, 2023 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENERATION BIO CO. Generation Bio Co., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that the name of the corporation is Generation Bio Co. and the original certificate of incorporation of the corporation was filed with the Secretary of State of the State of Delaw |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GEN |
|
| August 2, 2023 |
Generation Bio Reports Second Quarter 2023 Financial Results Second quarter 2023 cash balance of $314. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 10, 2023 |
Exhibit 10.1 By Electronic Mail March 17, 2023 Yalonda Howze *** *** RE: Offer of Employment Dear Yalonda: We are very excited to offer you the position of Chief Legal Officer where you will play an essential role in building Generation Bio’s foundation and long-term business and scientific success. Below are the terms of employment for your review and execution. If these terms are acceptable, ple |
|
| May 10, 2023 |
Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results Company entered into strategic collaboration with Moderna to use Generation Bio’s proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288. |
|
| May 10, 2023 |
Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENT between GENERATION BIO CO. and MODERNATX, INC. dated March 23, 2023 TABLE OF CONTENTS Page ARTICLE 1 - DEFINITIONS AND INTE |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GE |
|
| May 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 10, 2023 |
Exhibit 10.3 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. SHARE PURCHASE AGREEMENT By and Between MODERNATX, INC. AND GENERATION BIO CO. Dated as of March 23, 2023 TABLE OF CONTENTS Page 1. Definitio |
|
| April 26, 2023 |
Table of Contents will UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Filed by a Party other than the Registrant ☒ Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 10, 2023 |
Table of Contents will UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 4, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF GENERATION BIO CO. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Record Date for Stockholder Meetings 1 1.5 Notice of Meetings 1 1.6 Voting List 1 1.7 Quorum 2 1.8 Adjournments 2 1.9 Voting and Proxies 2 1.10 Action at Meeting 2 1.11 Nomination of Directors 3 1.12 Notice of Business |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 24, 2023 |
GBIO / Generation Bio Co / ModernaTX, Inc. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Generation Bio Co. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37148K100 (CUSIP Number) March 24, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| February 23, 2023 |
Subsidiaries of the registrant. Exhibit 21.1 Subsidiaries of the Registrant Entity Jurisdiction of Incorporation Generation Bio Securities Corporation Massachusetts |
|
| February 23, 2023 |
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results - Company expects to announce data for Factor VIII expression in non-human primates in 2023 - Strong cash balance of $279. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 14, 2023 |
GBIO / Generation Bio Co / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm235475d6sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Generation Bio Co. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 37148K100 (CUSIP Number) December |
|
| February 14, 2023 |
GBIO / Generation Bio Co / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 14, 2023 |
EX-99.B 2 d405438dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 9, 2023 |
GBIO / Generation Bio Co / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0971-generationbioco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Generation Bio Co. Title of Class of Securities: Common Stock CUSIP Number: 37148K100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate |
|
| February 1, 2023 |
GBIO / Generation Bio Co / Farallon Capital Partners, L.P. - AMENDMENT #3 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 12, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Generation Bio Co. |
|
| January 12, 2023 |
As filed with the Securities and Exchange Commission on January 12, 2023 As filed with the Securities and Exchange Commission on January 12, 2023 Registration No. |
|
| November 3, 2022 |
Exhibit 10.1 ? Generation Bio Co. ? ? ? ? December 8, 2017 ? Phillip Samayoa ? ? ? Dear Phillip: ? On behalf of Generation Bio. Co. (the "Company"), I am pleased to offer you employment with the Company on the following terms and conditions. ? 1. Position. You will be employed by the Company as a Senior Director of Corporate Development and Portfolio Strategy. It is contemplated that you will comm |
|
| November 3, 2022 |
Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results ? Cash balance of $301. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 15, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 6, 2022 |
GBIO / Generation Bio Co / PFM Health Sciences, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Generation Bio Co. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 37148K100 (CUSIP Number) August 25, 2022 (Date of Event Which Requires Fili |
|
| September 6, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Generation Bio Co., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the unders |
|
| August 4, 2022 |
Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results ? Cash balance of $312. |
|
| August 4, 2022 |
Exhibit 10.1 ? GENERATION BIO CO. Non-Employee Director Compensation Program Under Generation Bio Co.?s (the ?Company?) non-employee director compensation program, the Company pays its non-employee directors an annual fee. Each non-employee director receives an annual fee for service on the Company?s board of directors (the ?Board?) and for service on each committee on which the director is a memb |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission F |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| July 18, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 15, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission Fi |
|
| June 21, 2022 |
? Generation Bio Announces Update to Its GMP Manufacturing Strategy ? Company projects smaller GMP manufacturing footprint, enabled by further process development of rapid enzymatic synthesis of ceDNA at scale ? Company will seek to sublease its planned GMP facility, and will adopt a more capital efficient, modular, and flexible manufacturing approach ? Capital reallocated from facility buildout expected to extend cash runway into 2025 ? Cambridge, Mass. |
|
| June 21, 2022 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission Fi |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission Fil |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GE |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 5, 2022 |
Exhibit 10.2 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this "Amendment") is entered into as of this 24th day of February, 2022 (the "Effective Date"), by and between BMR-ROGERS STREET LLC, a Delaware limited liability company ("Landlord"), and GENERATION BIO CO., a Delaware corporation ("Tenant"). RECITALS A.WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of |
|
| May 5, 2022 |
Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results Company continues to optimize cell-targeted lipid nanoparticle (ctLNP) delivery system for nonviral genetic medicine applications in liver, retina and vaccines Cash balance of $337. |
|
| April 26, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? ? ? ? Filed by the Filed by a Party other than the Registrant ? ? Registrant ? ? ? Check the appropriate box: ? ? ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by |
|
| April 26, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 24, 2022 |
? ? Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results ? Well-capitalized with $375. |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commissio |
|
| February 24, 2022 |
Post-Effective Amendment No. 1 Table of Contents As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
Calculation of Filing Fee Table EX-FILING FEES 4 tmb-20220224xexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Generation Bio Co. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate |
|
| February 24, 2022 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment No 1 to Form S-3 (Form Type) Generation Bio Co. |
|
| February 24, 2022 |
? ? ?Exhibit 10.21 ? By Electronic Moil ? October 11, 2018 ? Antoinette Drahus Paone ? RE: Offer of Employment ? Dear Antoinette: ? We are very excited to offer you the position of Vice President, Regulatory Affairs where you will play an essential role in building Generation Bio's foundation and long -term business and scientific success. Below are the terms of employment for your review and exec |
|
| February 24, 2022 |
Subsidiaries of the registrant. Exhibit 21.1 ? Subsidiaries of the Registrant ? ? ? ? Entity Jurisdiction of Incorporation Generation Bio Securities Corporation ? Massachusetts ? |
|
| February 24, 2022 |
Exhibit 10.20 Torus Therapeutics, Inc. ? ? ? ? September 5, 2017 ? Matthew Stanton ? Dear Matt: On behalf of Torus Therapeutics (the "Company"), I am pleased to offer you employment with the Company on the following terms and conditions. 1.Position. You will be employed by the Company as the Chief Technology Officer. It is contemplated that you will commence employment on a date to be mutually agr |
|
| February 24, 2022 |
Exhibit 10.22 Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. ? AMENDMENT # 2 TO EXCLUSIVE LICENSE AGREEMENT Between Generation Bio and UMASS Chan Medical School ? This Amendment #2 (?Amendment 2?) expressly amends and relates to t |
|
| February 24, 2022 |
Non-Employee Director Compensation Program. Exhibit 10.23 ? GENERATION BIO CO. Non-Employee Director Compensation Program Under Generation Bio Co.?s (the ?Company?) non-employee director compensation program, the Company pays its non-employee directors an annual fee. Each non-employee director receives an annual fee for service on the Company?s board of directors (the ?Board?) and for service on each committee on which the director is a mem |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 11, 2022 |
GBIO / Generation Bio Co / Atlas Venture Fund X, L.P. - AMENDMENT TO SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Generation Bio Co. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| February 11, 2022 |
Atlas Venture Fund X, L.P. SC 13G/A Exhibit A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Generation Bio Co. and further agree that this agreement be included as an ex |
|
| February 11, 2022 |
GBIO / Generation Bio Co / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 11, 2022 |
GBIO / Generation Bio Co / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Generation Bio Co. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 10, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission |
|
| February 10, 2022 |
GBIO / Generation Bio Co / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Generation Bio Co. Title of Class of Securities: Common Stock CUSIP Number: 37148K100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ??Rule |
|
| February 3, 2022 |
GBIO / Generation Bio Co / FARALLON CAPITAL MANAGEMENT LLC - AMENDMENT #2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 10, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission |
|
| December 14, 2021 |
EX-99.1 2 gbio-20211214xex99d1.htm EX-99.1 Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program - Innovations in closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticle (ctLNP) production processes generated peak mean of 205% normal human factor VIII expression in mice - Non-human primates (NHPs) demonstrated up to 2% normal human factor VIII expression, and higher- |
|
| December 14, 2021 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commissio |
|
| November 10, 2021 |
? ? Generation Bio Reports Business Highlights and Third Quarter 2021 Financial Results ? New preclinical retinal data illustrating potential for expansive therapeutic applications of ctLNP delivery presented at ESGCT 2021 Annual Virtual Congress ? CAMBRIDGE, MASS. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commissio |
|
| November 10, 2021 |
? ? ? ? ? 41 SEYON STREET WALTHAM, MASSACHUSETTS ? ? Lease to ? GENERATION BIO CO. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 11, 2021 |
As filed with the Securities and Exchange Commission on August 11, 2021 Table of Contents As filed with the Securities and Exchange Commission on August 11, 2021 Registration No. |
|
| August 11, 2021 |
Generation Bio Reports Business Highlights and Second Quarter 2021 Financial Results Exhibit 99.1 ? ? ? Generation Bio Reports Business Highlights and Second Quarter 2021 Financial Results ? ? CAMBRIDGE, MASS., Aug. 11, 2021 - Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and second quarter 2021 financial results. ? ?This quarter we announced our shift |
|
| August 11, 2021 |
Exhibit 1.2 GENERATION BIO CO. $250,000,000 SALES AGREEMENT August 11, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Generation Bio Co., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the |
|
| August 11, 2021 |
Exhibit 4.4 GENERATION BIO CO. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Ina |
|
| August 11, 2021 |
Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| August 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission |
|
| August 11, 2021 |
Exhibit 4.3 GENERATION BIO CO. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplicab |
|
| August 11, 2021 |
Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| July 14, 2021 |
? ? ? Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update ? Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing ? Lease agreement signed to build an in-house RES manufacturing facility providing cGMP capacity for and internal control over clinical and initial commercial supply ? IND submission for hemophilia A now planned for 2023; factor VIII expression data with RES material in non-human primates expected year-end 2021 ? Cambridge, Mass. |
|
| July 14, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission Fi |
|
| June 10, 2021 |
Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission Fil |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission Fil |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 12, 2021 |
? ? Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports First Quarter Financial Results ? Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model ? Next-generation rapid enzymatic synthesis of closed-ended DNA further increases the efficiency and scale of the manufacturing platform ? Potent factor VIII construct optimized by taking advantage of the increased cargo capacity of closed-ended DNA ? CAMBRIDGE, MASS. |
|
| April 27, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2021 |
DEF 14A 1 tmb-20210609xdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Filed by a Party other than the Registrant ☒ Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of th |
|
| March 18, 2021 |
EX-99.1 Exhibit 99.1 Generation Bio Reports Fourth Quarter and Full Year 2020 Financial Results $262.3 million cash balance at the end of 2020 bolstered by additional net proceeds of $211.3 million from follow-on offering, funding key milestones into 2024 Ron Cooper appointed to Board of Directors Company remains on track to begin IND-enabling studies for hemophilia A in 2021 CAMBRIDGE, MASS., Mar |
|
| March 18, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 18, 2021 |
As filed with the Securities and Exchange Commission on March 18, 2021 Registration No. |
|
| March 18, 2021 |
Subsidiaries of the registrant. Exhibit 21.1 Subsidiaries of the Registrant Entity Jurisdiction of Incorporation Generation Bio Securities Corporation Massachusetts |
|
| March 18, 2021 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the capital stock and provisions of Generation Bio Co.?s (the ?Company,? ?we,? ?us? and/or ?our?) restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to our restated certif |
|
| March 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 18, 2021 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 17, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commissio |
|
| February 18, 2021 |
Generation Bio Appoints Ron Cooper to its Board of Directors Generation Bio Appoints Ron Cooper to its Board of Directors CAMBRIDGE, MASS., February 18, 2021 - Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has been appointed to its Board of Directors. The appointment is effective March 1, 2021. Ron Cooper is a global biopharmaceutical executive who currently s |
|
| February 16, 2021 |
Exhibit 1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the common stock, $0. |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) Generation Bio Co. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Generation Bio Co. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant |
|
| January 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 8, 2021 |
SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| January 7, 2021 |
Joint bookrunning managers J.P. Morgan Jefferies Cowen Lead manager Wedbush PacGrow 424B4 Table of Contents File Pursuant to Rule 424(b)(4) Registration No. 333-251872 Prospectus 8,000,000 shares Common stock We are offering 8,000,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Select Market under the symbol “GBIO.” The last reported sale price of our common stock on the Nasdaq Global Select Market on January 6, 2021 was $24.74 per |
|
| January 6, 2021 |
S-1MEF As filed with the Securities and Exchange Commission on January 6, 2021 Registration No. |
|
| January 4, 2021 |
CORRESP 1 filename1.htm Generation Bio Co. 301 Binney Street Cambridge, MA 02142 January 4, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Re: Generation Bio Co. Registration Statement on Form S-1 File No. 333-251872 Request for Acceleration Ladies and Gentlemen: Pursuan |
|
| January 4, 2021 |
Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 4, 2021 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 Generation Bio Co. [•] Shares of Common Stock Underwriting Agreement [•], 2021 J.P. Morgan Securities LLC Jefferies LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC |
|
| January 4, 2021 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on January 4, 2021 Registration No. |
|
| January 4, 2021 |
EX-10.20 Exhibit 10.20 By Electronic Mail August 22, 2018 Tracy Zimmermann, Ph.D. RE: Offer of Employment Dear Tracy, We are very excited to offer you the position of Vice President Preclinical and Translational Biology where you will play an essential role in building Generation Bio’s foundation and long -term business and scientific success. Below are the terms of employment for your review and |
|
| January 4, 2021 |
UW Acceleration Request J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Jefferies LLC 520 Madison Avenue New York, New York 10022 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10010 January 4, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Generation Bio Co. Registration St |
|
| December 21, 2020 |
DRS Table of Contents Confidential Treatment Requested by Generation Bio Co. Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the Securities and Exchange Commission on December 21, 2020. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED S |
|
| November 10, 2020 |
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 10, 2020 |
EX-99.1 Exhibit 99.1 Generation Bio Reports Third Quarter 2020 Business Updates and Financial Results On Track to Advance Lead Programs into Pre-Clinical Development in 2021 Supported by Key Leadership Team Appointments Cambridge, Mass. – Nov. 10, 2020 – Generation Bio Co. (Nasdaq: GBIO) is an innovative genetic medicines company creating a new class of non-viral gene therapy. Today the company re |
|
| November 10, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2020 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| August 11, 2020 |
10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GENERATION BIO C |
|
| August 11, 2020 |
EX-10.1 Exhibit 10.1 LEASE by and between BMR-ROGERS STREET LLC, a Delaware limited liability company and GENERATION BIO CO., a Delaware corporation TABLE OF CONTENTS Page 1. Lease of Premises 1 2. Basic Lease Provisions 2 3. Term 5 4. Possession and Commencement Date 5 5. Condition of Premises 8 6. Rentable Area 8 7. Rent 9 8. Rent Adjustments 10 9. Operating Expenses 10 10. Taxes on Tenant’s Pro |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2020 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 11, 2020 |
EX-10.2 Exhibit 10.2 By Electronic Mail July 6, 2020 Matthew Norkunas *** *** RE: Offer of Employment Dear Matthew: We are very excited to offer you the position of Chief Financial Officer where you will play an essential role in building Generation Bio’s foundation and long-term business and scientific success. Below are the terms of employment for your review and execution. If these terms are ac |
|
| August 11, 2020 |
Generation Bio Reports Business Updates and Second Quarter 2020 Financial Results EX-99.1 Exhibit 99.1 Generation Bio Reports Business Updates and Second Quarter 2020 Financial Results CAMBRIDGE, MASS., Aug. 11, 2020 — Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today reported recent business highlights and second quarter financial results. “The first half of 2020 has seen meaningful progress for Gen |
|
| July 24, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 21, 2020 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| June 26, 2020 |
GBIO / Generation Bio Co. / Artal International S.c.a. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) Generation Bio Co. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37148K100 (CUSIP Number) June 16, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| June 26, 2020 |
GBIO / Generation Bio Co. / Zone Healthcare Holdings, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 26, 2020 |
EX-1 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the common stock, $0. |
|
| June 16, 2020 |
GBIO / Generation Bio Co. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| June 16, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2020 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81- 4301284 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| June 16, 2020 |
EX-3.1 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF GENERATION BIO CO. Generation Bio Co., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that the name of the corporation is Generation Bio Co. and the original certificate of incorporation of the corporation was filed with the Secretary of State of the State of Delaware o |
|
| June 16, 2020 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF GENERATION BIO CO. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Record Date for Stockholder Meetings 1 1.5 Notice of Meetings 2 1.6 Voting List 2 1.7 Quorum 3 1.8 Adjournments 4 1.9 Voting and Proxies 4 1.10 Action at Meeting 4 1.11 Nomination of Directors 5 1.12 Notice of B |
|
| June 12, 2020 |
Joint bookrunning managers J.P. Morgan Jefferies Cowen Lead manager Wedbush PacGrow 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-238608 Prospectus 10,526,316 shares Common stock This is Generation Bio Co.’s initial public offering. We are selling 10,526,316 shares of our common stock. The public offering price is $19.00 per share. Currently, no public market exists for the shares. The shares will trade on the Nasdaq Global Select Market under the |
|
| June 12, 2020 |
S-8 As filed with the Securities and Exchange Commission on June 12, 2020 Registration No. |
|
| June 11, 2020 |
S-1MEF As filed with the Securities and Exchange Commission on June 11, 2020 Registration No. |
|
| June 11, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on June 11, 2020 Registration No. |
|
| June 9, 2020 |
Underwriter acceleration request J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Jefferies LLC 520 Madison Avenue New York, New York 10022 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10010 June 9, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Generation Bio Co. Registrat |
|
| June 9, 2020 |
CORRESP Generation Bio Co. 301 Binney Street Cambridge, MA 02142 June 9, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Courtney Lindsay Re: Generation Bio Co. Registration Statement on Form S-1 File No. 333-238608 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Se |
|
| June 8, 2020 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 Generation Bio Co. [●] Shares of Common Stock Underwriting Agreement [•], 2020 J.P. Morgan Securities LLC Jefferies LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC |
|
| June 8, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Generation Bio Co. (Exact name of registrant as specified in its charter) Delaware 81-4301284 (State of incorporation or organization) (I.R.S. Employer Identification No.) 301 Binney Street |
|
| June 8, 2020 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on June 8, 2020 Registration No. |
|
| June 8, 2020 |
EX-4.1 Exhibit 4.1 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 PO BOX 505006, Louisville, KY 40233-5006 CUSIP/IDENTIFIER XXXXXX XX X Holder ID XXXXXXXXXX Insurance Value 1,000,000.00 Number of Shares 123456 DTC 12345678 123456789012345 Certificate Numbers Num/No. Denom. Total 1234567890/1234567890 1 1 1 1234567890/1234567890 2 2 2 1234567890/1234567890 3 3 3 1234567890/1234567890 4 4 |
|
| June 8, 2020 |
EX-10.11 Exhibit 10.11 Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENT This Agreement, effective as of June 23, 2017 (the “Effective Date”), is between the University of Massachusetts (“University”), a n |
|
| June 8, 2020 |
EX-3.5 Exhibit 3.5 CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENERATION BIO CO. Generation Bio Co. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: A resolution was duly adopted by the Board of Directo |
|
| May 22, 2020 |
EX-10.3 Exhibit 10.3 GENERATION BIO CO. RESTRICTED STOCK AGREEMENT GRANTED UNDER 2017 STOCK INCENTIVE PLAN This Restricted Stock Agreement (the “Agreement”) is made this [ ] day of [ ], 20[ ], between Generation Bio Co., a Delaware corporation (the “Company”), and [ ] (the “Recipient”). For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows: 1. Issuance o |
|
| May 22, 2020 |
EX-10.18 Exhibit 10.18 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made effective as of September 26, 2019 (the “Effective Date”), by and between Generation Bio Co., a Delaware corporation, with its principal place of business being 301 Binney Street, Suite 401, Cambridge, MA 02142 (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability corporation, wi |
|
| May 22, 2020 |
EX-10.1 Exhibit 10.1 2017 STOCK INCENTIVE PLAN OF TORUS THERAPEUTICS, INC. TABLE OF CONTENTS PAGE 1. Purpose 1 2. Eligibility 1 3. Administration and Delegation 1 (a) Administration by the Board 1 (b) Appointment of Committees 1 4. Stock Available for Awards 2 (a) Number of Shares 2 (b) Substitute Awards 2 5. Stock Options 2 (a) General 2 (b) Incentive Stock Options 2 (c) Exercise Price. 3 (d) Dur |
|
| May 22, 2020 |
EX-4.2 Exhibit 4.2 EXECUTION VERSION GENERATION BIO CO. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 4 2.2 Company Registration 6 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 8 2.5 Furnish Information 9 2.6 Expenses of Registration 9 2.7 Delay of Registration 10 2.8 Indemnification |
|
| May 22, 2020 |
EX-10.10 Exhibit 10.10 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 20 by and between Generation Bio Co., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. [[Solely with respect to officers and d |
|
| May 22, 2020 |
EX-10.5 Exhibit 10.5 Generation Bio Co. STOCK OPTION AGREEMENT Generation Bio Co. (the “Company”) hereby grants the following stock option pursuant to its 2020 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Incentive Stock Option or Nonstatutory Stock Option: Number of shares of the Company’s |
|
| May 22, 2020 |
Exhibit 10.14 Torus Therapeutics, Inc. June 25, 2017 Douglas Kerr Dear Doug: On behalf of Torus Therapeutics (the ?Company?), I am pleased to offer you employment with the Company on the following terms and conditions. 1. Position. You will be employed by the Company as the Chief Scientific Officer and Executive Vice President of Research and Development. It is contemplated that you will commence |
|
| May 22, 2020 |
Consulting Agreement, dated January 2, 2019, by and between the registrant and Thomas Graney Exhibit 10.16 GENERATION BIO CO. CONSULTING AGREEMENT This Consulting Agreement (the ?Agreement?), made this 5th day of January, 2019 is entered into by Generation Bio Co., a Delaware corporation (the ?Company?), and Tom Graney, an individual residing at (the ?Consultant?). WHEREAS, the Company and the Consultant desire to establish the terms and conditions under which the Consultant will provide |
|
| May 22, 2020 |
EX-10.12 Exhibit 10.12 Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT NONEXCLUSIVE SUBLICENSABLE This Agreement is based on the model Patent License Non-Exclusive Sublicensable Agreem |
|
| May 22, 2020 |
Subsidiaries of the registrant Exhibit 21.1 Subsidiaries of the Registrant Entity Jurisdiction of Incorporation Generation Bio Securities Corporation Massachusetts |
|
| May 22, 2020 |
EX-3.2 Exhibit 3.2 BY-LAWS of TORUS THERAPEUTICS, INC. (the “Corporation”) 1. Stockholders (a) Annual Meeting. The annual meeting of stockholders shall be held for the election of directors each year at such place, date and time as shall be designated by the Board of Directors. Any other proper business may be transacted at the annual meeting. If no date for the annual meeting is established or sa |
|
| May 22, 2020 |
EX-3.3 Exhibit 3.3 RESTATED CERTIFICATE OF INCORPORATION OF GENERATION BIO CO. Generation Bio Co., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that the name of the corporation is Generation Bio Co. and the original certificate of incorporation of the corporation was filed with the Secretary of State of the State of Delaware o |
|
| May 22, 2020 |
EX-10.4 Exhibit 10.4 Generation Bio Co. 2020 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2020 Stock Incentive Plan (the “Plan”) of Generation Bio Co., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and |
|
| May 22, 2020 |
Exhibit 10.11 Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENT This Agreement, effective as of June 23, 2017 (the ?Effective Date?), is between the University of Massachusetts (?University?), a not-for-pr |
|
| May 22, 2020 |
Offer letter, dated December 14, 2018, by and between the registrant and Thomas Graney Exhibit 10.15 December 14, 2018 Tom Graney RE: Offer of Employment Dear Tom, We are very excited to offer you the position of Chief Financial Officer where you will play an essential role in building Generation Bio?s foundation and long-term business and scientific success. Below are the terms of employment for your review and execution. If these terms are acceptable, please sign and return a copy |
|
| May 22, 2020 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF GENERATION BIO CO. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Record Date for Stockholder Meetings 1 1.5 Notice of Meetings 2 1.6 Voting List 2 1.7 Quorum 3 1.8 Adjournments 4 1.9 Voting and Proxies 4 1.10 Action at Meeting 4 1.11 Nomination of Directors 5 1.12 Notice of Business |
|
| May 22, 2020 |
EX-10.13 Exhibit 10.13 Torus Therapeutics, Inc. October 12, 2017 Geoffrey McDonough Dear Geoff: On behalf of Torus Therapeutics, Inc. (the “Company”), I am pleased to offer you employment with the Company on the following terms and conditions. 1. Position. You will be employed by the Company as its President and Chief Executive Officer (“CEO”). It is contemplated that you will commence employment |
|
| May 22, 2020 |
CORRESP Stuart M. Falber +1 617 526 6663 (t) +1 617 526 5000 (f) wilmerhale.com [email protected] May 22, 2020 By Electronic Submission U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Courtney Lindsay Re: Generation Bio Co. Amendment 1 to Draft Registration Statement on Form S-1 Submitted May 12, 2020 CIK No. 000 |
|
| May 22, 2020 |
EX-10.19 Exhibit 10.19 By Electronic Mail [Date] [Name] [Street Address] [City, State ZIP] RE: Severance Plan Benefit Dear [Name]: Generation Bio (the “Company”) is pleased to set forth the severance benefits that you may be eligible to receive upon certain terminations of your employment with the Company (or its successor) under this letter agreement (“Agreement”). All other terms and conditions |
|
| May 22, 2020 |
Lease, dated August 2, 2018, by and between the registrant and BMR-Rogers Street LLC, as amended EX-10.9 Exhibit 10.9 LEASE by and between BMR-ROGERS STREET LLC, a Delaware limited liability company and GENERATION BIO CO., a Delaware corporation TABLE OF CONTENTS Page 1. Lease of Premises 1 2. Basic Lease Provisions 2 3. Term 5 4. Possession and Commencement Date 5 5. Condition of Premises 8 6. Rentable Area 8 7. Rent 9 8. Rent Adjustments 10 9. Operating Expenses 10 10. Taxes on Tenant’s Pro |
|
| May 22, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on May 22, 2020 Registration No. |
|
| May 22, 2020 |
Third Amended and Restated Certificate of Incorporation of the registrant EX-3.1 Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENERATION BIO CO. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Generation Bio Co., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That |
|
| May 22, 2020 |
Exhibit 10.8 Generation Bio Co. 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of this 2020 Employee Stock Purchase Plan (this ?Plan?) is to provide eligible employees of Generation Bio Co. (the ?Company?) and certain of its subsidiaries with opportunities to purchase shares of the Company?s common stock, $0.0001 par value per share (the ?Common Stock?), commencing at such time and on such dates as |
|
| May 22, 2020 |
EX-10.7 Exhibit 10.7 Generation Bio Co. RESTRICTED STOCK UNIT AGREEMENT Generation Bio Co. (the “Company”) hereby grants the following restricted stock units pursuant to its 2020 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of restricted stock units (“RSUs”) granted: Vesting Start Da |
|
| May 22, 2020 |
EX-10.6 Exhibit 10.6 Generation Bio Co. RESTRICTED STOCK AGREEMENT Generation Bio Co. (the “Company”) hereby grants the following award of restricted stock pursuant to its 2020 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of shares of the restricted common stock, $0.0001 par value pe |
|
| May 22, 2020 |
Exhibit 10.2 GENERATION BIO CO. STOCK OPTION AGREEMENT GRANTED UNDER 2017 STOCK INCENTIVE PLAN This Stock Option Agreement (this ?Agreement?) is made between Generation Bio Co., a Delaware corporation (the ?Company?), and the Participant pursuant to the 2017 Stock Incentive Plan (the ?Plan?). NOTICE OF GRANT I. Participant Information Participant: [] Participant Address: [] II. Grant Information G |
